20358-03-6

Basic information

• Product Name: 2-Amino-5-bromobenzothiazole
• Synonyms: 5-BROMO-BENZOTHIAZOL-2-YLAMINE;2-Amino-5-bromobenzothiazole;2-Amino-5-bromobenzothiazole.HBr;2-Amino-5-bromobenzothiazole hydrobromide;5-bromobenzo[d]thiazol-2-amine;2-Amino-5-bromo-1,3-benzothiazole;2-BenzothiazolaMine, 5-broMo-;5-broMo-2-BenzothiazolaMine
• CAS NO: 20358-03-6
• Molecular Formula: C₇H₅BrN₂S
• Molecular Weight: 229.1
• EINECS: 1308068-626-2
• Product Categories: Thiazoles;API;Thiazole;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;ThiazolesHeterocyclic Building Blocks;Building Blocks;C3 to C7;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks
• Mol File: 20358-03-6.mol
• Article Data: 15

Chemical Properties

• Melting Point: 194-198 °C
• Boiling Point: 366.848 °C at 760 mmHg
• Flash Point: 175.664 °C
• Appearance: White to brown/Solid
• Density: 1.837 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.783
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 3.43±0.10(Predicted)
• Water Solubility: Soluble in water.
• CAS DataBase Reference: 2-Amino-5-bromobenzothiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-5-bromobenzothiazole(20358-03-6)
• EPA Substance Registry System: 2-Amino-5-bromobenzothiazole(20358-03-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 20358-03-6(Hazardous Substances Data)

Usage

Chemical Properties

solid

Uses

2-Amino-5-bromobenzothiazole is used as pharmaceutical intermediates

InChI:InChI=1/C7H5BrN2S/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3H,(H2,9,10)

Upstream product

• 157645-54-0 4-bromo-2-nitro-1-thiocyanato-benzene 
• 875-51-4 4-Bromo-2-nitroaniline 
• 21327-14-0 1-(3-bromophenyl)thiourea 
• 854890-84-9 (2,5-dibromo-phenyl)-thiourea 
• 333-20-0 potassium thioacyanate 
• 591-19-5 m-Bromoaniline 
• 56967-17-0 m-bromoaniline hydrochloride 
• 1147550-11-5 ammonium thiocyanate 
• 824403-26-1 5-bromo-2-chlorobenzo[d]thiazole 
• 199475-45-1 5-bromo-1,3-benzothiazol-2(3H)-one 
• 93933-49-4 2-amino-4-bromobenzenethiol 
• 768-11-6 5-bromo-benzthiazole 
• 3425-46-5 potassium selenocyanate 

Downstream Products

• 1223564-51-9 1-benzoyl-3-(5-bromobenzo[d]thiazol-2-yl) thiourea 
• 1223564-43-9 1-(5-bromobenzo[d]thiazol-2-yl)-3-(4-nitrobenzoyl) thiourea 
• 1309261-76-4 C₂₁H₁₃BrN₄OS 
• 1309261-61-7 3-(5-bromo-1,3-benzothiazol-2-yl)-2-phenylquinazolin-4(3H)-one 
• 66820-95-9 2-bromo-10H-phenothiazine 
• 590417-69-9 2-amino-5-benzotriazoleboronic acid 
• 139192-88-4 2-amino-4-bromophenyl methyl sulphide 

Relevant articles and documents

PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2

Limited therapeutic options are available for the treatment of human schistosomiasis caused by the parasitic Schistosoma flatworm. The B cell lymphoma-2 (BCL-2)-regulated apoptotic cell death pathway in schistosomes was recently characterized and shown to share similarities with the intrinsic apoptosis pathway in humans. Here, we exploit structural differences in the human and schistosome BCL-2 (sBCL-2) pro-survival proteins toward a novel treatment strategy for schistosomiasis. The benzothiazole hydrazone scaffold previously employed to target human BCL-XL was repurposed as a starting point to target sBCL-2. We utilized X-ray structural data to inform optimization and then applied a scaffold-hop strategy to identify the 5-carboxamide thiazole hydrazone scaffold (43) with potent sBCL-2 activity (IC50 30 nM). Human BCL-XL potency (IC50 13 nM) was inadvertently preserved during the optimization process. The lead analogues from this study exhibit on-target activity in model fibroblast cell lines dependent on either sBCL-2 or human BCL-XL for survival. Further optimization of the thiazole hydrazone class is required to exhibit activity in schistosomes and enhance the potential of this strategy for treating schistosomiasis.

ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR

The present invention relates to compounds of formula (I) wherein G1 to G8 are as defined herein. The compounds are PK inhibitors and as such represent a new approach to treating pathogenic infections, including multidrug resistant pathogens. Disclosed herein are the compounds of formula (I), pharmaceutical compositions comprising the compounds of formula (I) and their use in the treatment of antimicrobial infection. (Formula (1))